|
Glioblastoma
|
|
|
|
G. Dresemann
Imatinib (STI 571)/ plus hydroxyurea: Safety and efficacy in pre-treated,
progressive Glioblastoma Multiforme (GBM) patients (pts): An update on the
initial 30 pts
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1516. (Clinical
Study)
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1516
|
|
G. Dresemann
Imatinib (STI571) plus hydroxyurea: Safety and
efficacy in pre-treated, progressive glioblastoma multiforme (GBM) patients
(pts)
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1550 (Clinical
Study)
|
|
G.
Dresemann
STI 571/hydroxyurea in progressive, pretreated
glioblastoma (GB) patients (pts.)
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
465 (Clinical Study)
|
|
Gregor
Dresemann
CD
117 (c-kit) - predictive for efficacy of imatinib in pretreated glioblastoma
patients?
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No.
2082
(Clinical Study)
|
|
M. Holdhoff, K. A. Kreuzer, C.
Appelt, R. Scholz, A. Jordan, B. Hildebrandt, C. A. Schmidt, R. A. Van Etten, B.
Dörken, P. Le Coutre
Combined administration of imatinib mesylate and
ionizing radiation leads to increased radiosensitivity in the human glioblastoma
cell line RuSi RS1
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1564 (Cell
Culture
Study)
|
|
Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, Buchdunger
E, Black PM, Stiles CD
Intracranial
inhibition of platelet-derived growth factor-mediated glioblastoma cell growth
by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class
Cancer Res 2000 Sep 15;60(18):5143-50 (Animal Study,
Abstract & Full Text)
|
|
E. Raymond, A.
Brandes, A. Van Oosterom, C. Dittrich, P. Fumoleau, B. Coudert,
C. Twelves, C. De Balincourt, D. Lacombe, M. Van Den Bent
Multicentre
phase II study of imatinib mesylate in patients with recurrent
glioblastoma: An EORTC: NDDG/BTG Intergroup Study
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1501 (Clinical
Study)
|
|
Huan Ren, Alf Giese,
Tingchang Chou, Steven Pelech, Nikolai Rainov
Biological activity of a novel tyrosine
kinase inhibitor of the 2-phenylaminopyrimidine class, Imatinib
(STI571, Gleevec), on human glioblastoma cells
Proceedings of the AACR, Volume 44, 2nd ed., July 2003, Abstract
No. R3776 (Cell Culture Study)
|
|
Patrick
Y Wen, W K Yung, Kenneth Hess, Sandra Silberman, Michael Hayes, David Schiff, Frank Lieberman, Timothy F
Cloughesy, Lisa M DeAngelis, Susan M Chang,
Larry Junck, Howard A Fine, Karen Fink, H I Robins, Jeffrey J Raizer, Lauren E
Abrey, Minesh P Mehta, Elizabeth A Maher, Peter M Black, John Kuhn, Renaud
Capdeville, Richard S Kaplan, Anthony Murgo, Charles Stiles, Michael D Prados
Phase I study of STI571 (Gleevec) for patients with
recurrent malignant gliomas and meningiomas (NABTC 99-08)
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No. 288
(Clinical Study)
|
|
|
Gliomas
|
|
|
|
M. van den Bent, A.
Brandes, M. Frenay, P. Fumoleau, R.
Stupp, C. Dittrich, B. Coudert, P.
Clement, D. Lacombe and E. Raymond
Multicentre phase II study of imatinib mesylate in patients with recurrent
anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and
anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug
Development Group (NDDG) and Brain Tumor Group (BTG) study
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1517. (Clinical
Study)
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1517
|
|
H. S. Friedman, J.
Quinn, J. Rich, J. Vredenburgh, A.
Desjardins, S. Sathornsumetee, A. Salvado,
Z. Nikolova, D. Bigner and D. Reardon
Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of
recurrent malignant glioma: Phase II study results
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1515. (Clinical
Study)
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1515
|
|
A. Katz, C. H. Barrios, R.
Abramoff, S. D. Simon, J. Tabacof, R. C. Gansl
Imatinib (STI 571) is active in patients (PTS) with
high-grade gliomas progressing on standard therapy
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1542 (Clinical
Study)
|
|
Landonio Giuseppe,
Riva Maurizio, Galli Carlo, Schiavo Roberta, Carminati Ornella, Secondino Simona,
Gambacorta Marcello, Defanti Carlo Alberto, Siena Salvatore
Overexpression
of c-kit oncogene in human brain tumors
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No.
295
(Cell Culture Study)
|
|
|
Reardon DA, Desjardins A, Vredenburgh JJ,
Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S,
McLendon R, Herndon Ii JE, Friedman AH, Salvado AJ, Friedman HS.
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus
temozolomide: Phase 1 trial in adults with malignant glioma
Neuro Oncol. 2008 Mar 21; [Epub ahead of print]
 Abstract |
DBLinks | BL 7:7
|
|
F.
S. Viola, F. Morrone, J. Stella, F. Spiller, A. Battastini, C. H. Barrios
Combination
of STI571 and temozolamide on inhibition of rat and human glioma cell lines
proliferation
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No. 469 (Cell Culture
Study)
|
|
|
Medulloblastoma
|
|
|
|
R. Morosetti, D. Meco, C. Dominici,
T. Servidei, A. Riccardi, A. M. Di Francesco, G. Cusano, R. Riccardi
Antitumor activity of imatinib mesylate in
medulloblastoma cell lines and xenografts
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.8554 (Animal
Study)
|
|
